HONOLULU (AP) - The University of Hawaii Cancer Center is the leader in a groundbreaking national study that found that early-stage breast cancer patients with the most common form of the disease do not benefit from chemotherapy.
The Honolulu Star-Advertiser reports the center helped develop the largest breast cancer study, enrolling 172 Hawaii patients onto the TailorX clinical trial, which found that hormone therapy alone produced results as good as both chemotherapy and hormone treatment for 70 percent of women post-surgery.
The five-year survival rate was 98 percent for women who received hormone pills alone and 98.1 percent for those who received both therapies.
At nine years, the rates were 93.9 percent and 93.8 percent, respectively.
The findings were based on 10,273 women who participated in the study from 2006 to 2010.